Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 570

1.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
2.

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B.

Cancer Immunol Immunother. 2018 Sep 14. doi: 10.1007/s00262-018-2244-7. [Epub ahead of print]

PMID:
30218171
3.

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.

Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X.

Ann Oncol. 2018 Sep 12. doi: 10.1093/annonc/mdy408. [Epub ahead of print]

PMID:
30215677
4.

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.

Makino E, Gutmann V, Kosnopfel C, Niessner H, Forschner A, Garbe C, Sinnberg T, Schittek B.

Cell Death Dis. 2018 Sep 11;9(9):930. doi: 10.1038/s41419-018-0952-8.

5.

Local interventions for actinic keratosis in organ transplant recipients: A systematic review.

Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, Berking C.

Br J Dermatol. 2018 Sep 6. doi: 10.1111/bjd.17148. [Epub ahead of print] Review.

PMID:
30188570
6.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12901. doi: 10.1111/ecc.12901. Epub 2018 Aug 20.

PMID:
30126009
7.

Vemurafenib.

Garbe C, Eigentler TK.

Recent Results Cancer Res. 2018;211:77-89. doi: 10.1007/978-3-319-91442-8_6.

PMID:
30069761
8.

Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Stec T, Keim U, Leiter U, Eigentler TK, Metzler G, Garbe C.

J Eur Acad Dermatol Venereol. 2018 Jul 27. doi: 10.1111/jdv.15194. [Epub ahead of print]

PMID:
30051517
9.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

10.

Quality assurance in melanoma care: The EU-MELACARE study.

Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningen S, Louwman M, Robsahm TE, Rutkwoski P, van Akkooi A, Zorzi M, Pasquali S, van de Velde C, Rossi CR.

Eur J Surg Oncol. 2018 Jul 3. pii: S0748-7983(18)31164-8. doi: 10.1016/j.ejso.2018.06.020. [Epub ahead of print]

PMID:
30001892
11.

Patientenakzeptanz und -vertrauen in die automatisierte, computergestützte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie.

Fink C, Uhlmann L, Hofmann M, Forschner A, Eigentler T, Garbe C, Enk A, Haenssle HA.

J Dtsch Dermatol Ges. 2018 Jul;16(7):854-860. doi: 10.1111/ddg.13562_g. No abstract available.

PMID:
29989363
12.

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.

Wagner NB, Forschner A, Leiter U, Garbe C, Eigentler TK.

Br J Cancer. 2018 Aug;119(3):339-346. doi: 10.1038/s41416-018-0167-x. Epub 2018 Jun 28.

PMID:
29950611
13.

Patient acceptance and trust in automated computer-assisted diagnosis of melanoma with dermatofluoroscopy.

Fink C, Uhlmann L, Hofmann M, Forschner A, Eigentler T, Garbe C, Enk A, Haenssle HA.

J Dtsch Dermatol Ges. 2018 Jul;16(7):854-859. doi: 10.1111/ddg.13562. Epub 2018 Jun 21.

PMID:
29927518
14.

YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.

Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, Forchhammer S, Grimmel C, Mertens PR, Hailfinger S, Dunn SE, Garbe C, Schittek B.

Mol Cancer Res. 2018 Jul;16(7):1149-1160. doi: 10.1158/1541-7786.MCR-17-0528. Epub 2018 May 9.

PMID:
29743296
15.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 Jun 7;7(6). pii: bio032656. doi: 10.1242/bio.032656.

16.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
17.

Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions.

Forschner A, Keim U, Hofmann M, Spänkuch I, Lomberg D, Weide B, Tampouri I, Eigentler T, Fink C, Garbe C, Haenssle HA.

Br J Dermatol. 2018 Aug;179(2):478-485. doi: 10.1111/bjd.16565. Epub 2018 Jun 7.

PMID:
29569229
18.

The iris signal: blue periphery, tan collaret and freckles pattern - strong indicators for epidermal skin cancer in South-Eastern Europe.

Grigore M, Furtunescu F, Minca D, Costache M, Garbe C, Simionescu O.

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1662-1667. doi: 10.1111/jdv.14929. Epub 2018 Mar 30.

PMID:
29524265
19.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

20.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

21.

Pediatric patients with cutaneous melanoma: A European study.

Brecht IB, De Paoli A, Bisogno G, Orbach D, Schneider DT, Leiter U, Offenmueller S, Cecchetto G, Godzinski J, Bien E, Stachowicz-Stencel T, Ben-Ami T, Chiaravalli S, Maurichi A, De Salvo GL, Sorbara S, Bodemer C, Garbe C, Reguerre Y, Ferrari A.

Pediatr Blood Cancer. 2018 Jun;65(6):e26974. doi: 10.1002/pbc.26974. Epub 2018 Jan 19.

PMID:
29350487
22.

The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival.

Ulmer A, Dietz K, Werner-Klein M, Häfner HM, Schulz C, Renner P, Weber F, Breuninger H, Röcken M, Garbe C, Fierlbeck G, Klein CA.

Eur J Cancer. 2018 Mar;91:1-10. doi: 10.1016/j.ejca.2017.12.002. Epub 2018 Jan 6.

PMID:
29316475
23.

How to use neoadjuvant medical treatment to maximize surgery in melanoma.

Amaral T, Tampouri I, Garbe C.

Expert Rev Anticancer Ther. 2018 Feb;18(2):121-130. doi: 10.1080/14737140.2018.1421460. Epub 2018 Jan 3.

PMID:
29271674
24.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
25.

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.

Gaiser MR, Skorokhod A, Gransheier D, Weide B, Koch W, Schif B, Enk A, Garbe C, Bauer J.

PLoS One. 2017 Nov 27;12(11):e0188602. doi: 10.1371/journal.pone.0188602. eCollection 2017.

26.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

27.

Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma.

Pereira PL, Krüger K, Hohenstein E, Welke F, Sommer C, Meier F, Eigentler T, Garbe C.

Eur Radiol. 2018 Apr;28(4):1456-1464. doi: 10.1007/s00330-017-5099-y. Epub 2017 Nov 9.

PMID:
29124381
28.

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T.

Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. No abstract available.

29.

Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP).

Offenmueller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Friedrich Classen C, Corbacioglu S, Dirksen U, Ebetsberger-Dachs G, Heinzerling L, Jorch N, Kuhlen M, Lawlor J, Niggli F, Streiter M, Schneider DT, Brecht I.

Klin Padiatr. 2017 Nov;229(6):322-328. doi: 10.1055/s-0043-118662. Epub 2017 Oct 10.

PMID:
29017184
30.

Safety of shortened infusion times for combined ipilimumab and nivolumab.

Gassenmaier M, Lipp HP, Scheu A, Wagner NB, Kofler L, Mueller A, Doecker D, Eigentler TK, Garbe C, Forschner A.

Cancer Immunol Immunother. 2018 Jan;67(1):135-140. doi: 10.1007/s00262-017-2075-y. Epub 2017 Oct 7.

PMID:
28988363
31.

'Corrigendum to "Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins" [Eur J Cancer 81 (August 2017) 203-205]'.

Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T.

Eur J Cancer. 2017 Dec;87:221. doi: 10.1016/j.ejca.2017.09.012. Epub 2017 Oct 3. No abstract available.

PMID:
28986136
32.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL.

J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.

33.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
34.

Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.

Amaral T, Leiter U, Garbe C.

Rev Endocr Metab Disord. 2017 Dec;18(4):517-532. doi: 10.1007/s11154-017-9433-0. Review.

PMID:
28916903
35.

The need for psycho-oncological support for melanoma patients: Central role of patients' self-evaluation.

Mayer S, Teufel M, Schaeffeler N, Keim U, Garbe C, Eigentler TK, Zipfel S, Forschner A.

Medicine (Baltimore). 2017 Sep;96(37):e7987. doi: 10.1097/MD.0000000000007987.

36.

Immunotherapy in managing metastatic melanoma: which treatment when?

Amaral T, Meraz-Torres F, Garbe C.

Expert Opin Biol Ther. 2017 Dec;17(12):1523-1538. doi: 10.1080/14712598.2017.1378640. Epub 2017 Sep 17. Review.

PMID:
28891339
37.

Durch Pembrolizumab verursachte Hepatitis: Diagnose und Behandlung.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037_g. No abstract available.

PMID:
28872244
38.

Pembrolizumab-induced hepatitis: diagnosis and treatment.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037. No abstract available.

PMID:
28872228
39.

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.

Seith F, Forschner A, Schmidt H, Pfannenberg C, Gückel B, Nikolaou K, la Fougère C, Garbe C, Schwenzer N.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):95-101. doi: 10.1007/s00259-017-3813-2. Epub 2017 Aug 22.

PMID:
28831583
40.

Reply to 'Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma'.

Amaral T, Garbe C.

Expert Opin Pharmacother. 2017 Oct;18(14):1537. doi: 10.1080/14656566.2017.1367596. Epub 2017 Aug 18. No abstract available.

PMID:
28812387
41.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C.

Eur J Cancer. 2017 Sep;83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review.

PMID:
28756137
42.

Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Eigentler TK, Keim U, Goebeler M, Fiedler E, Schuler G, Leiter U, Weide B, Grischke EM, Martus P, Garbe C.

J Invest Dermatol. 2017 Dec;137(12):2570-2577. doi: 10.1016/j.jid.2017.07.006. Epub 2017 Jul 21.

PMID:
28736231
43.

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study.

Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H.

J Invest Dermatol. 2017 Nov;137(11):2309-2315. doi: 10.1016/j.jid.2017.06.025. Epub 2017 Jul 21.

PMID:
28736229
44.

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.

Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.

45.

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients.

Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tüting T, Ulrich C, Wollina U, Hassel JC, Gutzmer R, Goerdt S, Zouboulis C, Leiter U, Eigentler TK, Garbe C.

Br J Dermatol. 2018 Feb;178(2):443-451. doi: 10.1111/bjd.15803. Epub 2017 Dec 20.

PMID:
28707317
46.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
47.

Imaging characteristics of cardiac metastases in patients with malignant melanoma.

Zitzelsberger T, Eigentler TK, Krumm P, Nikolaou K, Garbe C, Gawaz M, Klumpp B.

Cancer Imaging. 2017 Jul 1;17(1):19. doi: 10.1186/s40644-017-0122-8.

48.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698
49.

Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.

Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T.

Eur J Cancer. 2017 Aug;81:203-205. doi: 10.1016/j.ejca.2017.05.018. Epub 2017 Jun 20. No abstract available. Erratum in: Eur J Cancer. 2017 Dec;87:221.

PMID:
28641200
50.

S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0.

Eigentler TK, Mühlenbein C, Follmann M, Schadendorf D, Garbe C.

J Dtsch Dermatol Ges. 2017 Jun;15(6):e1-e41. doi: 10.1111/ddg.13247. No abstract available.

PMID:
28591444

Supplemental Content

Support Center